Pharmaceutical policies in Canada: another example of federal-provincial discord
- PMID: 10701389
- PMCID: PMC1231173
Pharmaceutical policies in Canada: another example of federal-provincial discord
Abstract
Pharmaceutical policy in Canada is set at both the federal and provincial levels of government. The federal government is responsible for intellectual property rights of manufacturers (patents) and the initial approval and labelling of prescription drugs and for ensuring overall market competitiveness. The provincial government has responsibility and jurisdiction over the funding of all health care services, including pharmaceuticals. Various interactions between the pharmaceutical industry, the federal and provincial governments and consumers have shaped the current landscape for prescription drugs in Canada. One key failing of the system is that the federal government is almost completely insulated from the impact of its policies because, although it regulates drug prices, it does not buy any drugs. In contrast, provincial governments have no jurisdiction over market competitiveness or pricing, yet end up paying for most of the drug expenditures incurred.
Similar articles
-
Points to consider about prescription drug prices: an overview of federal policy and pricing studies.Clin Ther. 1993 Jul-Aug;15(4):726-38. Clin Ther. 1993. PMID: 8221823 Review.
-
Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.J Health Polit Policy Law. 2010 Oct;35(5):705-42. doi: 10.1215/03616878-2010-025. J Health Polit Policy Law. 2010. PMID: 21123668
-
The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.Nurs Econ. 2005 Nov-Dec;23(6):307-11, 279. Nurs Econ. 2005. PMID: 16459902 Review.
-
The effect of generic competition on the price of brand-name drugs.Health Policy. 2004 Apr;68(1):47-54. doi: 10.1016/j.healthpol.2003.07.007. Health Policy. 2004. PMID: 15033552
-
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.JAMA. 2016 Aug 23-30;316(8):858-71. doi: 10.1001/jama.2016.11237. JAMA. 2016. PMID: 27552619 Review.
Cited by
-
Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations.CMAJ. 2011 Sep 6;183(12):E817-23. doi: 10.1503/cmaj.101800. Epub 2011 Jul 11. CMAJ. 2011. PMID: 21746822 Free PMC article.
-
Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.Pharmacoeconomics. 2002;20(9):577-91. doi: 10.2165/00019053-200220090-00002. Pharmacoeconomics. 2002. PMID: 12141886 Review.
-
The content of patient counseling about interchangeable medicines and generic substitution in Finnish community pharmacies - a survey of dispensers.BMC Health Serv Res. 2019 Dec 11;19(1):956. doi: 10.1186/s12913-019-4798-2. BMC Health Serv Res. 2019. PMID: 31829174 Free PMC article.
-
A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.Healthc Policy. 2016 Aug;12(1):18-36. Healthc Policy. 2016. PMID: 27585023 Free PMC article.
-
Children in need of Pharmacare: medication funding requests at the Toronto Hospital for Sick Children.Can J Public Health. 2003 Mar-Apr;94(2):121-6. doi: 10.1007/BF03404584. Can J Public Health. 2003. PMID: 12675168 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
